A New Era of Diabetic Kidney Disease Treatment with Sodium-glucose Cotransporter-2 Inhibitors

Overview

Journal J Diabetes Investig

Specialty Endocrinology

Date 2022 Jan 14

PMID 35029051

Authors

Shinji Kume

Hiroshi Maegawa

Affiliations

Soon will be listed here.

Abstract

SGLT2 inhibitors may have a potential to stop the decline of renal function independent of the stage of albuminuria in diabetic kidney disease, and can be a new light in the post-RAS inhibitor era.

Citing Articles

Effectiveness and safety of sodium-glucose cotransporter 2 inhibitors in Asian populations.

Ha K, Kim D J Diabetes Investig. 2023; 15(3):285-287.

PMID: 37988221 PMC: 10906014. DOI: 10.1111/jdi.14111.

Six-Month Periodic Fasting in Patients With Type 2 Diabetes and Diabetic Nephropathy: A Proof-of-Concept Study.

Sulaj A, Kopf S, von Rauchhaupt E, Kliemank E, Brune M, Kender Z J Clin Endocrinol Metab. 2022; 107(8):2167-2181.

PMID: 35661214 PMC: 9282263. DOI: 10.1210/clinem/dgac197.

A new era of diabetic kidney disease treatment with sodium-glucose cotransporter-2 inhibitors.

Kume S, Maegawa H J Diabetes Investig. 2022; 13(5):765-767.

PMID: 35029051 PMC: 9077719. DOI: 10.1111/jdi.13747.

References

Kume S, Maegawa H . A new era of diabetic kidney disease treatment with sodium-glucose cotransporter-2 inhibitors. J Diabetes Investig. 2022; 13(5):765-767. PMC: 9077719. DOI: 10.1111/jdi.13747. View

Heerspink H, Karasik A, Thuresson M, Melzer-Cohen C, Chodick G, Khunti K . Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. Lancet Diabetes Endocrinol. 2019; 8(1):27-35. DOI: 10.1016/S2213-8587(19)30384-5. View

. Recommendations on the Proper Use of SGLT2 Inhibitors. J Diabetes Investig. 2019; 11(1):257-261. PMC: 6944824. DOI: 10.1111/jdi.13160. View

Neuen B, Ohkuma T, Neal B, Matthews D, de Zeeuw D, Mahaffey K . Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program. J Am Soc Nephrol. 2019; 30(11):2229-2242. PMC: 6830803. DOI: 10.1681/ASN.2019010064. View

Nagasu H, Yano Y, Kanegae H, Heerspink H, Nangaku M, Hirakawa Y . Kidney Outcomes Associated With SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs in Real-world Clinical Practice: The Japan Chronic Kidney Disease Database. Diabetes Care. 2021; 44(11):2542-2551. PMC: 8546274. DOI: 10.2337/dc21-1081. View

Wada T, Mori-Anai K, Kawaguchi Y, Katsumata H, Tsuda H, Iida M . Renal, cardiovascular and safety outcomes of canagliflozin in patients with type 2 diabetes and nephropathy in East and South-East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical.... J Diabetes Investig. 2021; 13(1):54-64. PMC: 8756319. DOI: 10.1111/jdi.13624. View

Hirai T, Kitada M, Monno I, Oda E, Hayashi Y, Shimada K . Sodium-glucose cotransporter 2 inhibitors in type 2 diabetes patients with renal function impairment slow the annual renal function decline, in a real clinical practice. J Diabetes Investig. 2021; 12(9):1577-1585. PMC: 8409862. DOI: 10.1111/jdi.13502. View

Utsunomiya K, Koshida R, Kakiuchi S, Senda M, Fujii S, Kurihara Y . Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus treated in real-world clinical practice: Results of a 36-month post-marketing surveillance study (J-STEP/LT). J Diabetes Investig. 2020; 12(2):184-199. PMC: 7858109. DOI: 10.1111/jdi.13333. View

Matsuba I, Kawata T, Iemitsu K, Asakura T, Amemiya H, Ishikawa M . Effects of ipragliflozin on the development and progression of kidney disease in patients with type 2 diabetes: An analysis from a multicenter prospective intervention study. J Diabetes Investig. 2020; 11(5):1248-1257. PMC: 7477528. DOI: 10.1111/jdi.13248. View

10.

Araki E, Goto A, Kondo T, Noda M, Noto H, Origasa H . Japanese Clinical Practice Guideline for Diabetes 2019. J Diabetes Investig. 2020; 11(4):1020-1076. PMC: 7378414. DOI: 10.1111/jdi.13306. View

11.

Kobayashi K, Toyoda M, Hatori N, Furuki T, Sakai H, Sato K . Sodium-glucose cotransporter 2 inhibitor-induced reduction in the mean arterial pressure improved renal composite outcomes in type 2 diabetes mellitus patients with chronic kidney disease: A propensity score-matched model analysis in Japan. J Diabetes Investig. 2020; 12(8):1408-1416. PMC: 8354503. DOI: 10.1111/jdi.13491. View

12.

Kume S, Araki S, Ugi S, Morino K, Koya D, Nishio Y . Secular changes in clinical manifestations of kidney disease among Japanese adults with type 2 diabetes from 1996 to 2014. J Diabetes Investig. 2018; 10(4):1032-1040. PMC: 6626952. DOI: 10.1111/jdi.12977. View

13.

Horii T, Oikawa Y, Atsuda K, Shimada A . On-label use of sodium-glucose cotransporter 2 inhibitors might increase the risk of diabetic ketoacidosis in patients with type 1 diabetes. J Diabetes Investig. 2021; 12(9):1586-1593. PMC: 8409873. DOI: 10.1111/jdi.13506. View

14.

Perkovic V, Jardine M, Neal B, Bompoint S, Heerspink H, Charytan D . Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019; 380(24):2295-2306. DOI: 10.1056/NEJMoa1811744. View

15.

Brenner B, Cooper M, de Zeeuw D, Keane W, Mitch W, Parving H . Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001; 345(12):861-9. DOI: 10.1056/NEJMoa011161. View

16.

Kashiwagi A, Araki S, Maegawa H . Sodium-glucose cotransporter 2 inhibitors represent a paradigm shift in the prevention of heart failure in type 2 diabetes patients. J Diabetes Investig. 2020; 12(1):6-20. PMC: 7779279. DOI: 10.1111/jdi.13329. View